Skip to main content
. 2017 Aug 21;114(36):E7441–E7449. doi: 10.1073/pnas.1705013114

Fig. 3.

Fig. 3.

Evaluation of a PARP1-targeted diagnostic strategy. (A) Physiochemical properties of the PARPi-FL probe. (B) Schema of the experimental spectrofluorimetry procedure for measurement of PARPi-FL concentrations in spleen and lymph nodes of DLBCL and B6 mice. (C) Spectrofluorimetry measurement of PARPi-FL accumulation in DLBCL mice (n = 5) and B6 mice (n = 5). The concentration of PARPi-FL is presented as the percentage of injected dose per gram of tissue (%ID/g). (D) PARPi-FL accumulation in lymph nodes as measured by %ID. (E) PARPi-FL accumulation in spleen as measured by %ID. (F) Preexposure of olaparib blocks the accumulation of PARPi-FL in the lymph nodes and spleen of DLBCL mice. (G) Representative confocal microscopic images of lymph node sections from DLBCL mice with PARPi-FL injection or blocking with olaparib. (H) Flow cytometry gating procedure to identify B cells from the lymph nodes of DLBCL or B6 mice injected with PARPi-FL. (I) Flow cytometry enumeration showing the percentage of B cells out of all CD45+ immune cells in the lymph nodes and spleen. (J) Quantification of average PARPi-FL level in B cells by flow cytometry as measured by the mean fluorescence intensity (MFI). The numbers over the short bars indicate MFI value (×10,000). Error bars represent SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, nonparametric Student’s t test.